Esophageal Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 33 expanded access programs, clinical trials, and compassionate use pathways listed for Esophageal Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with esophageal cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 22 in other lifecycle stages. Sponsors actively running programs in this area include Merck Sharp & Dohme LLC, AstraZeneca, Brown University, Case Comprehensive Cancer Center, Cedars-Sinai Medical Center, and others.
By recruiting status
Snapshot of where every Esophageal Cancer program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive22
Top sponsors
Organisations running the most Esophageal Cancer programs in the directory.
- Merck Sharp & Dohme LLC2 programs
- AstraZeneca1 program
- Brown University1 program
- Case Comprehensive Cancer Center1 program
- Cedars-Sinai Medical Center1 program
- Daiichi Sankyo1 program
- Diwakar Davar1 program
- Immunitas Therapeutics1 program
- Intima Bioscience, Inc.1 program
- Jazz Pharmaceuticals1 program
Esophageal Cancer programs (33)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on Carboplatin, Nab-Paclitaxel, and Durvalumab Before Surgery for Head and Neck Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on Using CYTALUX™ for Imaging Gastrointestinal Cancers During Surgery — Cedars-Sinai Medical Center
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
- Proton Beam Therapy vs. Intensity-Modulated Radiation Therapy for Esophageal Cancer — M.D. Anderson Cancer Center
- PULSO Trial: Comparing Pulsed Low-Dose-Rate Radiation with Standard Radiation for Esophageal Cancer — Medical College of Wisconsin
- Pilot Study on Using CYTALUX for Detecting Cancer During Surgery — John Waters
- Study on Sonesitatug Vedotin and Capecitabine, With or Without Rilvegostomig, for Advanced Stomach and Esophageal Cancer — AstraZeneca
- Study on VMD-928 Alone and with Pembrolizumab for Treating Solid Tumors or Lymphoma with High TrkA Levels — VM Oncology, LLC
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Merus N.V.
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on Using Genetically Modified Immune Cells to Treat Metastatic Gastrointestinal Cancers — Intima Bioscience, Inc.
- Study of Pembrolizumab with Trastuzumab and Chemotherapy for Esophagogastric Cancer — Memorial Sloan Kettering Cancer Center
- Study on PRT3789 and Pembrolizumab for Advanced or Metastatic Solid Tumors with SMARCA4 Mutation — Prelude Therapeutics
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on TAK-500 With or Without Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors — Takeda
- Study on Trastuzumab Deruxtecan and Nivolumab for Patients Free of Disease After Treatment for HER-2 Positive Esophageal and Gastroesophageal Cancers — Brown University
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on the Feasibility of Using the LUM Imaging System to Detect Gastrointestinal Cancers — Lumicell, Inc.
- Study on Liquid Nitrogen Spray Cryotherapy Before Chemotherapy for Esophageal Cancer — Case Comprehensive Cancer Center
- Study on Oral Q702 and Pembrolizumab for Advanced Esophageal, Gastric, Liver, and Cervical Cancers — Qurient Co., Ltd.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on Sacituzumab Tirumotecan with Pembrolizumab and Chemotherapy for Advanced Gastroesophageal Cancer — Merck Sharp & Dohme LLC
- Study on Combination Therapies for Second Line Treatment in Advanced Gastroesophageal Cancer — Merck Sharp & Dohme LLC
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Esophageal Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.